InspireMD Inc. (NSPR)

InspireMD's stock has been impacted by several events in the past six months. The company reported Q3 2025 earnings exceeding expectations and initiated the U.S. commercial launch of CGuard Prime. InspireMD raised $58 million in gross proceeds. Earlier in the year, the company reported a wider-than-expected Q1 loss, though revenue topped estimates. NSPR stock has traded between $1.51 and $3.80 over the past 52 weeks.

Information regarding specific demand seasonality for InspireMD, Inc.'s products and services is not explicitly detailed in the provided search results.

InspireMD, Inc. is a medical device company specializing in MicroNet stent platform technology for vascular and coronary diseases. Its major products include the CGuard Carotid Embolic Prevention System (CGuard EPS), CGuard Prime Stent System, MGuard Prime Embolic Protection System (MGuard Prime EPS), and SwitchGuard Neuroprotection System.

InspireMD, Inc. has an international presence in Europe, Latin America, the Middle East, and the Asia Pacific, including countries like Italy, Germany, and Russia. It is headquartered in Miami, Florida, and has initiated a U.S. commercial launch of its CGuard Prime system.

InspireMD has maintained a positive brand reputation over the past year due to clinical advancements and regulatory successes for its CGuard Prime carotid stent system. The company received FDA PMA approval and CE Mark approval for the CGuard Prime Embolic Prevention System. Clinical trial results were published in the Journal of the American College of Cardiology. InspireMD has highlighted external clinical evidence supporting carotid artery stenting combined with medical therapy. The company's products are frequently highlighted at conferences, and InspireMD has received a consensus rating of "Buy" from analysts.

InspireMD, Inc. has 44 institutional owners and shareholders holding a total of 23,152,071 shares, representing approximately 44.78% of the stock. Major institutional owners include Rosalind Advisors, Inc., Nantahala Capital Management, LLC, and Standard Life Aberdeen plc. Insiders have sold more stock than they have bought in the past three months.